Introduction
• Metastatic colorectal cancer (mCRC) is a disease that has spread beyond the large intestine and nearby lymph nodes.
• Liver resection can offer long-term survival in patients with mCRC. However, the majority of such patients are not eligible for liver resection upon diagnosis due to widespread nature of their disease.
• Chemotherapy can significantly downsize primarily unresectable metastases and offer the possibility of resection in mCRC patients.
• Chemotherapy with cetuximab (CET) (Erbitux R
⃝,
Merck Serono) * and panitumumab (PAN) (Vectibix R ⃝, Amgen) * appears to be more effective for patients with RAS (rat sarcoma) WT (wild type) tumors (i.e., tumors without mutations in KRAS/NRAS exons 2/3/4).
• The National Institute for Health and Care Excellence (NICE) is conducting a multiple technology appraisal (MTA) to review the clinical and costeffectiveness of combination chemotherapies with CET and PAN for people with previously untreated RAS WT mCRC, not eligible for liver surgery.
• Preliminary cost-effectiveness results of this study are presented here.
* The use of the trade names is for identification purposes only and does not imply endorsement by the authors, the NHS, the NIHR, MRC, CCF, NETSCC, the NIHR HTA Programme or the Department of Health.
Methods

Model overview
We proposed an economic model estimating medical costs and health benefits of CET and PAN compared to treatments currently available in the NHS (Fig. 1 ). • Model type: Markov model • Target population: 1 st line mCRC patients not eligible for liver surgery (base case), and the subpopulation of patients with liver-confined metastases (scenario analysis)
• Treatment arms: base case ( Network meta-analysis
• The analysis was based on five RCTs identified from a systematic review of evidence.
• Two networks were generated:
FOLFOXcontaining chemotherapy regimens and FOLFIRIcontaining chemotherapy regimens (Fig. 2) . 
Results
Base case
CET and PAN do not appear cost-effective at the willingness-to-pay (WTP) threshold of £20,000 per QALY gained, compared to chemotherapy alone (FOLFOX or FOLFIRI) ( Table 1) .
Potentially not cost-effective at zero price ICERs remain above £20,000 even under zero prices for CET and PAN (Table 1) . 
Sensitivity analyses
The likelihood of being the most cost-effective treatment at the WTP of £20,000 per QALY gained ( Fig.  3 ):
• CET+FOLFOX: 22%
• PAN+FOLFOX: 0%
• CET+FOLFIRI: 0% The major sources of prediction uncertainties:
• Proportion of patients undergoing liver resection • PFS for unresected patients, and PFS and OS postresection
• Treatment duration
Conclusions
Although CET and PAN appear to be clinically beneficial for RAS WT mCRC patients, they are likely to represent poor value for money when judged by costeffectiveness criteria used in England and Wales.
